Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Finished Goods (2017 - 2023)

Perspective Therapeutics (CATX) has disclosed Finished Goods for 11 consecutive years, with $20000.0 as the latest value for Q3 2023.

  • Quarterly Finished Goods fell 25.93% to $20000.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $20000.0 through Sep 2023, down 25.93% year-over-year, with the annual reading at $21000.0 for FY2022, N/A changed from the prior year.
  • Finished Goods hit $20000.0 in Q3 2023 for Perspective Therapeutics, up from $18000.0 in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $49000.0 in Q2 2021 to a low of $7000.0 in Q4 2019.
  • Historically, Finished Goods has averaged $22368.4 across 5 years, with a median of $21000.0 in 2022.
  • Biggest five-year swings in Finished Goods: crashed 72.97% in 2019 and later soared 314.29% in 2021.
  • Year by year, Finished Goods stood at $7000.0 in 2019, then changed by 0.0% to $7000.0 in 2020, then skyrocketed by 314.29% to $29000.0 in 2021, then decreased by 27.59% to $21000.0 in 2022, then fell by 4.76% to $20000.0 in 2023.
  • Business Quant data shows Finished Goods for CATX at $20000.0 in Q3 2023, $18000.0 in Q2 2023, and $15000.0 in Q1 2023.